SCHEMBL18650901

SCHEMBL18650901

Nc1nc2cc(N3CCOCC3=O)ccc2n1C1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 10/20 0.46
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ GFER P55789 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ HCAR1 Q9BXC0 1/20 0.43
▸ PRKACA P17612 4/20 0.41
▸ GSK3B P49841 4/20 0.41
▸ ROCK1 Q13464 3/20 0.41
▸ F10 P00742 1/20 0.41
▸ OGFRL1 Q5TC84 2/20 0.41
▸ RPS6KB1 P23443 2/20 0.40
▸ OPRM1 P35372 1/20 0.39
▸ OPRD1 P41143 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18650909 0.90 PTGS2 (0.40) PTGS2PRKACAGSK3BROCK1F10
SCHEMBL23618026 0.89 PTGS2 (0.41) PTGS2PRKACAGSK3BROCK1F10
SCHEMBL23617944 0.89 PTGS2 (0.41) PTGS2PRKACAGSK3BROCK1F10
SCHEMBL18668039 0.87 PTGS2 (0.40) PTGS2F10
SCHEMBL18668092 0.87 PTGS2 (0.40) PTGS2PRKACAGSK3BROCK1F10
SCHEMBL18650911 0.86 PIK3CA (0.39) PTGS2F10OGFRL1OPRM1OPRK1
SCHEMBL18667872 0.86 PIK3CA (0.39) PTGS2F10OGFRL1OPRM1OPRK1
SCHEMBL18650891 0.82 GPR119 (0.37) PTGS2PRKACAGSK3BROCK1F10
SCHEMBL18650890 0.82 GPR119 (0.37) PTGS2PRKACAGSK3BROCK1F10
SCHEMBL23617960 0.82 PKM (0.40) PTGS2F10RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3350177-B1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2021-07-07 — — EP disclosed
US-10392375-B2 Heteroaryl compounds as IRAK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2019-08-27 — — US disclosed
WO-2017049068-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-03-23 — — WO disclosed
US-20170081317-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-03-23 — — US disclosed
US-20170081317-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-03-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081317-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF IRAK2, IRAK3, IRAK1 PTGS2 3203/4885KDM4E 729/4885ALDH1A1 2580/4885
US-10392375-B2 Heteroaryl compounds as IRAK inhibitors and uses thereof IRAK2, IRAK3, IRAK1 PTGS2 3203/4885KDM4E 729/4885ALDH1A1 2580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback